Lipocalin 2 protects from lung tumorigenesis associated
with gut microbiota alterations
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Our group has shown that loss of G protein coupled receptor, class C, group 5, member A
(Gprc5a-/-) leads to tumors after exposure to the carcinogen nicotine-specific nitrosamine
ketone (NNK) that harbor the driver mutation KrasG12D found in human KM-LUAD (3). We
further found progressive lipocalin 2 (Lcn2) elevation during inflammation and LUAD
development. Lcn2 is an anti-microbial protein that was shown to sequester iron-laden
siderophores essential for bacterial metabolism and prevent the overgrowth of bacterial species
associated with inflammation and carcinogenesis (2). Lcn2 loss increased LUAD tumorigenesis,
supporting its tumor protective effects (1). Tumor burden after NNK exposure was associated
with progressive and distinct changes in gut microbiome composition in Gprc5a-/- and Gprc5a-/-/
Lcn2-/- mice. This suggests that Lcn2 loss could be implicated in microbial dysbiosis and may
explain the ensuing increased tumor burden. To address this hypothesis, we investigated the
effects of gut microbiome modulation in a syngeneic lung cancer mouse model using fecal
microbiota transfer (FMT).
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Lung adenocarcinoma (LUAD), the most common cancer diagnosed in smokers, frequently
exhibits somatic mutations in the KRAS oncogene (1). KRAS-mutant LUAD (KM-LUAD)
displays dismal prognosis warranting new strategies for early interception. Limiting advances is
poor understanding of early events in pathogenesis. Growing evidence shows the microbiome
is a key player in modulating host immune response, tumorigenesis, and response to therapy
(2). Yet, our knowledge of the gut-lung axis is still in its infancy.
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Figure 1. Gut microbiome changes
during the phenotypic evolution of
tobacco carcinogen-associated LUAD. A,
B. Gut microbiome α-diversity evaluated
using the Shannon index of Gprc5a-/- (A)
and Gprc5a-/-/ Lcn2-/- (B) fecal samples
collected at Baseline, end of NNK, 3-,
and 7-month post-NNK. C. Bray-Curtis
and OTU-based clustering of fecal
samples showing segregation based on
genotype (axis 1) and timepoint
(baseline, end of NNK, three and seven
months post-NNK; axis 2).

Axis 2

C

Axis 1

0

10

15

20

Days

C

D
Figure 3. A, B. Average and individual tumor
volumes in Gprc5a-/- (A) and 129-Elite (B) mice
following subcutaneous tumor cell implantation.
Red denotes mice receiving FMT derived from
Gprc5a-/- animals and blue denotes mice
receiving FMT derived from Gprc5a-/-/Lcn2-/mice. *, P ≤ 0.05; **, P ≤ 0.01. C, D. Mesenteric
lymph nodes (indicated by white arrows)
from Gprc5a-/- mice that received FMT
from Gprc5a-/-/ Lcn2-/- feces (C) compared to
mice receiving FMT derived from Gprc5a-/- feces
donors (D). E. Erythematous and inflamed
Peyer’s patches (white arrows) from Gprc5a-/mouse receiving FMT from Gprc5a-/-/ Lcn2-/feces.
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Figure 2. Upper panel. Antibiotic cocktail was continuously
supplied to each of Gprc5a-/- or 129-Elite WT mice in water for
two weeks. Recipients (from each genotype) received FMT
derived from either Gprc5a-/- or Gprc5a-/-/Lcn2-/- feces via oral
gavage for two weeks. 5 million mF471 cells or 2 million LKR13
cells were then subcutaneously injected into Gprc5a-/- and 129Elite WT mice, respectively. FMT continued for 3 more weeks
following injection and tumors were measured twice weekly
starting at day 5 post-injection using a digital caliper. At endpoint
(tumor volume ≥ 2000mm3), fecal pellets and blood were
collected. Left panel. The lamina propria, Peyer’s patches, and
mesenteric lymph nodes were also collected for downstream
analyses. Adapted from Moretto MM et al., PLOS Pathogens,
2012.

Our FMT experiments conducted in two different syngeneic models highlight a novel protective role for gutspecific microbiome homeostasis in the development of LUAD. Our novel findings show that Lcn2 is
critically important to control bacterial community makeup against bacteria that perpetuate LUAD
tumorigenesis.
• We will perform 16S rRNA sequencing on fecal samples obtained during our FMT experiments. Future
experiments will involve iron chelators and narrow-spectrum antibiotics to target specific tumor-promoting
bacteria.
• We will further validate our findings in a lung carcinogenesis model; Gprc5a-/- and Gprc5a-/-/Lcn2-/- mice
exposed to NNK will receive FMT derived from Gprc5a-/- and Gprc5a-/-/Lcn2-/- feces.
• Single-cell RNA sequencing and flow cytometry analyses will be done on tumor plugs and mesenteric lymph
nodes to assess the immune contexture and trajectories taking place from the gut to the systemic circulation.

References

1. Treekitkarnmongkol W, et al. American Journal of
Respiratory and Critical Care Medicine. 2021.
2. Moschen AR, et al. Cell Host & Microbiome. 2016.
3. Fujimoto J, et al. International Journal of Cancer. 2017.

Acknowledgments
•
•

Many thanks to Dr. Humam Kadara, Dr. Zahraa Rahal, Dr. Ansam
Sinjab, and Yuejiang Liu for their mentorship; Dr. Shine Chang,
Dr. Melinda Yates, and Kava Lewis for making CPRTP possible.
This research was supported by a training grant from the National
Cancer Institute (R25 CA56452, Dr. Shine Chang, Principal
Investigator).

